This article was originally published in The Gray Sheet
Collaboration with a research group at The Toronto Hospital will develop cell-based therapies to treat cardiovascular disease. The partners' initial focus is on developing a treatment involving transplantation of cultured autologous cardiomyocytes into the scar tissue that replaces heart muscle after a heart attack. Clinical trials are expected to begin in the second half of 2000. Genzyme gains rights to the technology in exchange for funding all R&D and commercialization efforts
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.